Key result
New PtfV1(+) at discharge significantly increased the risk of major adverse cardiovascular events compared to persistent PtfV1(-) in NSTE-ACS patients (HR 2.993).
Why the study?
Does the dynamic development of P-wave terminal force in lead V1 (PtfV1) predict long-term MACEs in patients with NSTE-ACS?
Population
595 patients with confirmed non-ST-segment elevation acute coronary syndrome who received coronary angiography
Comparison
Persistent PtfV1 ECG at admission and discharge… vs Persistent PtfV1(-) ECG at admission and discharge
Design
Cohort
Follow-up
24.71 ± 1.95 months
Authors
Loading...
New PtfV1(+) at discharge signals higher MACE risk in NSTE-ACS; hypothesis-generating for dynamic monitoring pending prospective validation.
Cohort (n=595)
No
Does the dynamic development of P-wave terminal force in lead V1 (PtfV1) predict long-term MACEs in patients with NSTE-ACS?
Hazard Ratio: 2.993 (95% CI 1.66–5.397)
Absolute Event Rate: 21.3% vs 8.6%
p-value: p=0.000
Dynamic changes in PtfV1 during hospitalization, specifically persistent or new PtfV1 positivity at discharge, are significant predictors of long-term MACEs in patients with NSTE-ACS.
Li et al. (2015) conducted a cohort in Non-ST-segment elevation acute coronary syndrome (NSTE-ACS) (n=595). New PtfV1(+) at discharge vs. Persistent PtfV1(-) at admission and discharge was evaluated on Major adverse cardiovascular events (MACEs) (HR 2.993, 95% CI 1.660-5.397, p=0.000). New PtfV1(+) at discharge significantly increased the risk of major adverse cardiovascular events compared to persistent PtfV1(-) in NSTE-ACS patients (HR 2.993).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: